The potential of lipid mediator networks as ocular surface therapeutics and biomarkers
- 29 April 2020
- journal article
- research article
- Published by Elsevier in The Ocular Surface
- Vol. 19, 104-114
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 152 references indexed in Scilit:
- Change in Prostaglandin Expression Levels and Synthesizing Activities in Dry Eye DiseaseOphthalmology, 2012
- Infection regulates pro-resolving mediators that lower antibiotic requirementsNature, 2012
- Aspirin-Triggered Lipoxin A4 (15-epi-LXA4) Increases the Endothelial Viability of Human Corneas Storage in Optisol-GSJournal of Ocular Pharmacology and Therapeutics, 2011
- UVB light regulates expression of antioxidants and inflammatory mediators in human corneal epithelial cellsBiochemical Pharmacology, 2011
- Knockdown of heme oxygenase-2 impairs corneal epithelial cell wound healingJournal of Cellular Physiology, 2010
- Resolvin E1 Improves Tear Production and Decreases Inflammation in a Dry Eye Mouse ModelJournal of Ocular Pharmacology and Therapeutics, 2010
- Resolution, the grail for healthy ocular inflammationExperimental Eye Research, 2010
- Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxificationProceedings of the National Academy of Sciences, 2010
- Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammationNature Immunology, 2008
- Resolvin E1 and protectin D1 activate inflammation-resolution programmesNature, 2007